The Mucosal and Vaccine Research Colorado (MAVRC) program promotes disease prevention by fostering collaborative and innovative research to understand human immunology, mucosal and vaccine biology.
Mucosal tissues are the moist surfaces of the body that provide the first line of host defense. These surfaces most often successfully exclude harmful elements from the body. However, the most common infections (pneumonia, ear and urinary tract infections, gingivitis, diarrhea and HIV/AIDS) and cancers (lung, colon, breast, and prostate) begin at the mucosa.
Creative solutions to prevent infections, cancer and immunologic diseases can only succeed if diverse investigators work and think together across preconceived boundaries. MAVRC endeavors to identify support to integrate the talents, both conceptual and technical, of University of Colorado scientists and clinicians who recognize, and strive to combat, the problems that affect our state, our country, and our world.
__________________________________________________________________________________
These paylines apply to applications going to the May 2011 Council Meetings.
- R01 - New Investigator - 14%
- R01 - Seasoned Investigator - 10%
- R21 - 24 Overall Score
NIAID: Understanding Paylines and Percentiles
Starting in FY 2010, NIH changed the way it calculates overall impact scores. For Unsolicited R01's reviewed by the NIH Center for Scientific Review, NIH converts the overall impact score into a percentile.
-
A percentile ranks your application relative to the other applications reviewed by your study section as its last three meetings
-
A percentile roughly translates to the percentage of applications receiving better overall impact score from the study section during one year
-
Percentiles range from 1 to 99 in whole numbers. Rounding is always up, e.g., 10.1% becomes 11
-
In contrast to usual mathmatical practice, a lower number indicates a better score.
__________________________________________________________________________________
New NIH Opportunities
|
RFA-AI-11-036
|
Strategies for the Protection of Pregnant
Women and Infants Against Infectious
Diseases (R01) |
|
The purpose of this FOA is to encourage new and innovative mechanistic studies of pathogens that impact placental function and fetal well-being, with the long-term goal of informing the development of interventions against these pathogens and reducing the burden of infection-related pregnancy loss and infant morbidity and mortality. |
| Letter of Intent Due: September 13, 2011 |
Application Due: October 13, 2011 |
|
|
|
|
RFA-AI-11-027 |
Therapeutics for Neurotropic Biodefense
Toxins and Pathogens (R21/R33) |
|
To support basic to translational research focused on development of new therapeutic strategies for neurotropic intoxication or infection caused by select biodefense pathogens. |
| Letter of Intent Due: September 23, 2011 |
Application Due: October 24, 2011 |
|
|
|
Learning Event